Cholesterol-lowering effects and potential mechanisms of chitooligosaccharide capsules in hyperlipidemic rats.

Yao Jiang,Guihua Liu,Chuhan Fu,Zhengquan Su,Jiao Guo

doi:10.29219/fnr.v62.1446

Yao Jiang, Guihua Liu + Show 3 more

Open Access

https://doi.org/10.29219/fnr.v62.1446

Copy DOI

Abstract

BackgroundChitooligosaccharide (COS) has shown potential antihyperlipidemic activity in a few studies as a functional food.MethodWe investigated the cholesterol-lowering effect and potential mechanisms of chitooligosaccharide capsules (COSTC) in male SD rats fed a high-fat diet.ResultsCOSTC could ameliorate serum lipid levels. Simultaneously, the cholesterol-lowering effect is probably attributed to its role in two pathways: upregulating the gene expression and activity of cholesterol 7α-hydroxylase (CYP7A1), liver X receptor alpha (LXRA), and peroxisome proliferation activated receptor-α (PPARα), which facilitates the conversion of cholesterol into bile acid; downregulating the gene expression and activity of enzymes including 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and sterol-responsive element binding protein-2 (SREBP2) and upregulating the low-density lipoprotein receptor (LDLR) to reduce the denovo synthesis of cholesterol.ConclusionStudies have suggested that COSTC has potential usefulness as a natural supplement or functional food for preventing and treating hyperlipidemia.

Highlights

Chitooligosaccharide (COS) has shown potential antihyperlipidemic activity in a few studies as a functional food
Based on the analysis of differential gene expression in the liver tissues of hyperlipidemic rats, which was closely related to the hepatic hyperlipidemic response, we investigated the antihyperlipidemic effects of COST capsules (COSTC) using high-fat diet-induced rats, and the results demonstrated that COSTC can ameliorate lipid metabolism and its related complications
In this study, we demonstrated that COSTC improved lipid metabolism via the upregulation of the gene expression and activity of CYP7A1, liver X receptor alpha (LXRA), and peroxisome proliferation activated receptor-α (PPARα), which promotes the conversion of cholesterol into bile acid, downregulating the gene expression and activity of enzymes, including hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and sterol-responsive element binding protein-2 (SREBP2), and upregulating low-density lipoprotein receptor (LDLR) to reduce the de novo synthesis of cholesterol

Summary

Introduction

Chitooligosaccharide (COS) has shown potential antihyperlipidemic activity in a few studies as a functional food. Method: We investigated the cholesterol-lowering effect and potential mechanisms of chitooligosaccharide capsules (COSTC) in male SD rats fed a high-fat diet. The cholesterol-lowering effect is probably attributed to its role in two pathways: upregulating the gene expression and activity of cholesterol 7α-hydroxylase (CYP7A1), liver X receptor alpha (LXRA), and peroxisome proliferation activated receptor-α (PPARα), which facilitates the conversion of cholesterol into bile acid; downregulating the gene expression and activity of enzymes including 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and sterol-responsive element binding protein-2 (SREBP2) and upregulating the low-density lipoprotein receptor (LDLR) to reduce the denovo synthesis of cholesterol. Conclusion: Studies have suggested that COSTC has potential usefulness as a natural supplement or f unctional food for preventing and treating hyperlipidemia

Methods

Results

Discussion

Conclusion